Equities
Health CareMedical Equipment and Services
  • Price (EUR)46.36
  • Today's Change0.50 / 1.09%
  • Shares traded419.87k
  • 1 Year change-10.33%
  • Beta0.5029
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Eurofins Scientific SE's net income fell -49.16% from 610.10m to 310.20m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 77.46% to 79.07%.
Gross margin22.02%
Net profit margin9.32%
Operating margin14.02%
Return on assets5.94%
Return on equity11.25%
Return on investment7.22%
More ▼

Cash flow in EURView more

In 2023, Eurofins Scientific SE increased its cash reserves by 152.67%, or 737.70m. The company earned 1.02bn from its operations for a Cash Flow Margin of 15.63%. In addition the company generated 413.60m cash from financing while 681.10m was spent on investing.
Cash flow per share6.17
Price/Cash flow per share7.30
Book value per share27.40
Tangible book value per share-1.61
More ▼

Balance sheet in EURView more

Eurofins Scientific SE has a Debt to Total Capital ratio of 40.09%, a lower figure than the previous year's 62.58%.
Current ratio1.42
Quick ratio1.34
Total debt/total equity0.676
Total debt/total capital0.4009
More ▼

Growth rates in EUR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -50.00% and -21.09%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
Div yield(5 year avg)0.90%
Div growth rate (5 year)11.66%
Payout ratio (TTM)33.45%
EPS growth(5 years)9.19
EPS (TTM) vs
TTM 1 year ago
13.11
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.